Ge Healthcare
(Nasdaq: Gehc)
announced today that it had launched its premium offer from the automated breast ultrasound of Invenia (abuse).
The latest 3D ultrasound offer of the company includes advanced AI and other innovative features. It aims to drive more quickly, reproducible additional screening and to rationalize exam readings on patients with dense breasts.
Ge Healthcare has announced the new offer at the same time that it extends its partnership in AI with NVIDIA to include autonomous X -ray and ultrasound applications. (We have a full overview of Medtech Ai News of the NVIDIA GTC 2025 event this week.)
The Medtech giant, based in Chicago, says that around 71% of cancers occur in dense breasts. Studies in the United States and Europe show that 40% of women (over 70% of Asian women) have dense breast tissues, according to society. He notes growing evidence supporting abuse as a tool to detect cancer in these dense breasts with lighter and more detailed images. Abuse can also improve the sensitivity of the detection of invasive cancer in dense breasts when added to mammography.
Designed to manage high volumes of patients along the breast care route, Invenia Abus also offers high -quality images and stimulates clinical confidence. New Verisound IA tools can help clinicians work more intelligently and more efficiently, depending on the company. The tools have an assessment of the quality of scanning for an immediate qualitative assessment during the examination. Its new rapid scanning tool increases the scanning speed up to 40% and the CSound Imageform capabilities automatically create a focus with each pixel. This guarantees image quality and coherent reproducibility with high resolution.
Doctors can use the Indenia abuse spectator with an AI assistant to examine and quickly interpret patient exams. They can assess exams from their practice or from a distance. AI for examination tools use intelligent algorithms to help detect and characterize breast lesions.
Ge Healthcare plans to launch invenia abuse premium, which has a pre-marked approval of the FDA, in key countries throughout 2025.
“Women with dense breasts are often faced with poorer results due to malignant tumors detected at stages later and more advanced. Invenia premium abuse equipped with an AI has the potential to optimize the screening capacities of clinicians, which allows them to detect cancers at an early stage, said Karley Yoder, CEO of comparve Caresound compar. “Invenia abuse premium is designed to help provide the best possible results for patients while prioritizing patient experience with functionality to improve scanning speed and improve comfort during an exam.”
